Dynavax Technologies intends to price public offering of common stock

Deal funds commercial launch of Heplisav, general corporate purposes

By Devika Patel

Knoxville, Tenn., Nov. 2 - Dynavax Technologies Corp. plans a public offering of common stock, according to a prospectus supplement filed Wednesday with the Securities and Exchange Commission. The deal will have a 30-day greenshoe.

Cowen and Co. and William Blair & Co. are the underwriters.

Proceeds will be used for activities related to the expected approval and commercial launch of Heplisav and for other general corporate purposes, including working capital.

Dynavax is a Berkeley, Calif.-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.